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Abstract The implantable cardioverter defibrillator (ICD)
has significantly improved survival in patients with an in-
creased risk of sudden cardiac death (SCD). The wearable
cardioverter defibrillator (WCD) is an alternative to the ICD
in patients with a transient ICD indication or those in whom
an ICD temporarily cannot be implanted. We describe here
the technical details of the WCD and report three patients
who were treated with a WCD in an outpatient setting. The
WCD allowed the cardiac condition of two patients to
improve to such an extent that permanent ICD implantation
was deemed unnecessary. This new form of therapy may
result in significant cost reduction, avoidance of unneces-
sary ICD implantation, and increased patient satisfaction.
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Introduction
The implantable cardioverter defibrillator (ICD) has signif-
icantly improved survival in patients with an increased risk
of sudden cardiac death (SCD) [1, 2]. Patients who are at
risk of or have survived a life-threatening arrhythmia are
eligible for ICD treatment according to the current guide-
lines [3, 4]. However, pro-arrhythmic conditions may mod-
ify over time; in particular, the left ventricular ejection
fraction (LVEF) may improve, resulting in a change in
ICD indication. It might therefore take time before a
definitive indication for ICD implantation can be estab-
lished. On the other hand, if an ICD needs to be removed
due to infection or technical problems, the patient’s risk of
SCD remains unaltered.
In these cases the wearable cardioverter defibrillator
(WCD) can be used as a temporary protection for SCD.
The WCD is a non-invasive alternative to an ICD and may
serve as a bridge to recovery such that ICD implantation can
be avoided or postponed.
The first clinical use of the WCD was described in 2000
[5]. It is effective in defibrillating life-threatening ventricu-
lar arrhythmias without bystander intervention [6]. We de-
scribe here the first use of the WCD in the Netherlands. In
this contribution we report the technical details and clinical
practice in three cases.
Technical details
The only WCD currently available in the Netherlands is the
LifeVest 3,100 (LifeVest® Zoll-Lifecor, Pittsburgh, USA)
[7]. The system consists of two main components: (1) an
electrode belt and garment that surrounds the patient’s chest,
and (2) a monitor that the patient wears around the waist or
from a shoulder strap, shown in Fig. 1. Washable garments
are available in sizes to suit most patients. The WCD elec-
trodes are dry and non-adhesive to the skin. The monitor
weighs about 800 g. The device contains pushbuttons and
indicators for the user, and a speaker for alarms and voice
prompts.
Treatment sequence
After detection of ventricular fibrillation (VF), the WCD has
a response time of 25 s (programmable up to 55 s) to allow
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threshold for VF identification can be set from 120 to 250
beats/min, with a default of 200 beats/min. If the system
identifies VT, there is a response time of 60 s (programma-
ble up to 180 s). The threshold for VT identification can be
programmed from 120 to the VF threshold, with a default
setting of 150 beats/min. During normal operation, the vi-
bration alarm activates before the siren alarm. If an arrhyth-
mia is detected during the sleep interval (which can be
programmed), the vibration and siren alarms activate
simultaneously.
Directly prior to delivering a defibrillating shock, gel is
released from the electrodes to lower skin impedance and
yield optimal shock efficacy. The entire event, from arrhyth-
mia detection to shock delivery, typically takes less than one
minute. If the arrhythmia continues after the first shock, up
to 5 additional shocks may be given. The shock energy can
be programmed to between 75 and 150 joules (±5%), with a
default setting of 150 joules.
Preventing inappropriate therapy
The key difference between the WCD and conventional
ICDs is the opportunity given to the patient to interrupt the
treatment cycle. When the alarm sounds as a result of
arrhythmia detection, a conscious patient can stop the treat-
ment. This prevents inappropriate arrhythmia detection from
becoming inappropriate shocks. If the patient holds the two
response buttons at any time during the treatment sequence,
the alarm will stop and no shocks will be delivered. If the
patient releases the response buttons, the device continues to
give alarms, spoken warnings to bystanders, and ultimately
delivers a shock.
ECG recording of events
The patient’s ECG is stored for all detected arrhythmias.
ECGs can alsobe recordedmanually bypressingthe response
buttons on the device. Patients transmit device information
telephonicallytothe LifeVest Networkfromwhere physicians
can then access the data (ECG recordings, patient use, electri-
calinterference,andotherdevice-relatedinformation)through
an encrypted internet connection.
Clinical practice
In our clinic we consider patients suitable for a WCD if they
are at high risk for SCD and meet criteria for ICD implan-
tation, but ICD implantation is precluded because of one of
the following:
1. Primary prevention patients at high risk due to extremely
low LVEF or therapy refractory nonsustained ventricular
tachycardias (NSVT):
Fig. 1 Anterior and posterior view of LifeVest
Fig. 2 Typical treatment
sequence during VF
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waiting period)
b. After recent CABG or PTCA (coverage during the
90 day ICD waiting period)
c. Listed for cardiac transplant
d. Recently diagnosed nonischaemic cardiomyopathy
(to evaluate the result of optimal medical therapy)
2. Temporary medical condition precludes implantation
(e.g. systemic infectious process)
3. Awaiting ICD re-implantation
We instruct eligible patients on the use and maintenance
of the WCD. The patient is therefore admitted to the cardi-
ology ward for at least 24 h to get comfortable with the
device and the alarm signals.
An automatic external defibrillator (AED) is issued for
occasions when the patient is not protected against SCD
because of not wearing the WCD (e.g. during showering,
garment changes). Partner, family and/or caretakers are
instructed about AED use in these unprotected situations.
Outpatients are followed up 2 and 4 weeks after receiving
the WCD, followed by monthly visits. During follow-up the
arrhythmic events, patients’ compliance and device use are
evaluated. Also, a quality of life assessment is performed.
An ICD technician and/or a cardiologist are available 24 h a
day, 7 days a week for troubleshooting.
Case reports
We first started using the WCD in 2009 and describe three
cases below.
Case 1
A 64-year-old woman was admitted to our clinic with dilat-
ed cardiomyopathy with a poor LVEF (19% on MRI) result-
ing from viral myocarditis. A nonsustained ventricular
tachycardia (NSVT) of 230 beats/min was observed. The
low LVEF and NYHA class II-III constituted a class I
indication for ICD implantation. However, LVEF might
recover in patients with viral cardiomyopathy after optimal
medical therapy for several months. Therefore, we post-
poned ICD implantation. The recording of an NSVT, how-
ever, indicated a high short-term risk for SCD. To allow her
expected LVEF recovery in an outpatient setting we used the
WCD in this patient for 3 months.
After a few days of wearing the WCD in our clinic the
patient was discharged. Two manual events and one auto-
matic event (noise) were recorded. There were no recorded
VT/VF episodes. There was a very high compliance, but the
patient decided not to use the WCD in the last week because
of increasing wearing discomfort.
Three months after the start of WCD therapy her condi-
tion had improved significantly. Her LVEF increased to
39% and she was functionally in NYHA class I. Therefore,
implantation of an ICD was no longer indicated.
Case 2
A 22-year-old male with a genetic predisposition to SCD
due to the DPP6 haplotype was admitted with an acute
Staphylococcus aureus pocket infection and sepsis after
recent ICD implantation for primary prevention. Infection
occurred after the patient manipulated the sutures of his
wound.
The ICD was removed on the day of admission. The
patient was admitted for several days for observation and
intravenous antibiotic treatment. It was his specific request
to have the new ICD implanted in the same position as the
previous ICD. Our advice was to let the infected pocket
recover for at least two months, and offered the patient the
WCD to bridge this period in an outpatient setting.
The compliance of this patient was about 80% because of
wearing discomfort and esthetical reasons. During the use of
the WCD, 6 manual events and 20 automatic events were
recorded All 20 automatic events were due to noise. There
were no recorded episodes of VT/VF.
The infection had completely recovered after 2 months
and a new ICD was implanted without complications in the
same position. After 12 months of follow-up there were no
signs of recurring infection.
Case 3
A 41-year-old male was referred to our clinic for ICD
implantation as secondary prevention for idiopathic dilated
cardiomyopathy and an episode of syncope. The patient had
an excessive lifestyle and was familiar with abuse of alcohol,
nicotine and intravenous drugs. Initial echocardiographic
evaluation showed a dilated left ventricle and a poor LVEF.
The coronary arteries were normal at angiography. The
MRI confirmed a dilated cardiomyopathy with a poor left
and right ventricular function, the calculated LVEF was
18%. Taking into consideration the patient’s lifestyle, we
postulated that the cardiomyopathy might have resulted
from alcohol toxicity.
No ventricular arrhythmias were recorded during admis-
sion. Medical treatment for heart failure was instituted,
alcohol intake was prohibited and ICD implantation was
deferred. We decided to bridge a period of 3 months with
high risk of SCD with the WCD to allow the LVEF to
improve.
During follow-up 1 manual event and 1 automatic event
(noise) were recorded. There were no events of VT/VF.
During the initial 2 months compliance was over 80%, in
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wearing discomfort.
After a period of three months the LVEF had fully recov-
ered (EF: 60%). Therefore, ICD implantation was no longer
indicated.
Conclusion
We describe here the first clinical experience in the Nether-
lands with the WCD for the prevention of SCD. We could
avoid unnecessary ICD implantation in two of our cases
because of improvement of the patient’s condition over
time. In one case the WCD was used as a bridge to ICD
re-implantation after device infection.
The cost of the WCD is considerable, and currently not
reimbursed, but the costs only amount to approximately
20% of hospital admission in a telemetry monitored ward.
For patients at increased risk for SCD, admission and te-
lemetry is the only safe alternative for ICD implantation.
Costs are further being saved when ICD implantation can be
avoided, which was the case in two of the three patients that
we describe. In addition to the cost issue, patients valued
staying at home higher than hospital admission, evident
from increased quality of life (not shown).
The safety of the WCD is a matter of ongoing debate.
Feldman et al. report 289 patients of whom 6 patients who
were not or incorrectly wearing the device died [6]. In their
study 6 out of 8 appropriate shocks were successful. The
two unsuccessful therapy attempts, one of which was non-
fatal because of external defibrillation, both resulted from
incorrect wearing of the device [6]. Meltendorf et al. dem-
onstrated that 3 of the 4 VT/VF episodes were successfully
terminated, and no patients experienced inappropriate WCD
discharges [5]. These findings stress the importance of cor-
rect use of the WCD. This deserves attention, since our
patients all experienced wearing discomfort, resulting from
pressure sores from the electrodes, the weight of the monitor
unit, the amount of false alarms and discomfort in the
summer season. These issues resulted in different degrees
of suboptimal protection for SCD.
This compliance-related suboptimal protection and the
reports of patients who died not wearing the WCD [6] led
us to think of a strategy to increase the safety of WCD
therapy. It is virtually impossible to fit an unconscious
patient with his/her WCD in an emergency setting. When
therapy from a WCD is ineffective due to incorrect wearing
it might be very difficult to correct this within a few
minutes. For these situations we supply the patient’s care-
takers with an AED and instruct them on how to use this
device. The AED serves as a backup device for the WCD.
To our knowledge, we are the only group that attempts to
protect the patient against SCD with an AED during the
time that the WCD is not worn because of showering and
garment changes. This strategy might increase the safety of
this noninvasive alternative to ICD implantation.
The introduction of a new, smaller WCD (Zoll Medical
LifeVest 4000) may potentially result in better patient com-
pliance. Unfortunately this device is not yet available in the
Netherlands.
We cannot draw conclusions on the efficacy of the WCD,
since our patients did not experience appropriate therapy. It
is of note, however, that no inappropriate shocks occurred
either. This is congruent with Everitt’s experience who
reports no appropriate or inappropriate shocks with the
WCD in children [8]. Feldman et al. describe an incidence
of unnecessary shocks of 0.67% per month per patient use
[6] which seems less than reported by Grimm et al. for the
ICD [9].
It is likely that the use of the WCD in the Netherlands
will further expand, and more knowledge will be acquired
about patient compliance, effectiveness, usefulness and per-
formance of the WCD. Klein et al. recently reviewed and
summarised the experience with the WCD in 43 different
hospitals in Germany [10]. They found that the WCD is
effective in providing immediate lifesaving defibrillation,
and that the device might contribute to better selection of
patients for ICD therapy [10]. In their report, only 43% of
WCD patients were eventually implanted with an ICD. This
complements our findings.
Indeed, many patients who are implanted with an ICD
never experience any appropriate therapy, even during long-
term follow-up [11, 12]. This might underscore the need for
a more accurate indication and a more detained attitude
towards ICD implantation.
The WCD can be used to postpone or avoid ICD implan-
tation in patients with a transient ICD indication or those in
whom an ICD cannot be implanted temporarily. This new
form of therapy may result in significant cost reduction (no
long hospital stays), avoidance of unnecessary ICD implan-
tation, and increased patient satisfaction. However, care
needs to be taken to assure correct use of the device.
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